Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV), By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes,Others) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Prostate Cancer Diagnostic Market size was valued at USD 126.5 billion in 2022. It is expected to reach USD 225.4 billion by 2028, at a CAGR of 8.6% from 2023 to 2029. Prostate cancer is the most common type of cancer in men it is characterized by the abnormal development of cells in the prostate gland and it may extend in the surrounding parts of the prostate gland. The prostate cancer diagnostics market is classified on the basis of product type, age, cancer stage, and geography. Prostate cancer is age-dependent cancer risk of prostate cancer increases with an increase in age, family history, chemical exposure, smoking, inflammation of prostate and infections are other risk factors for prostate cancer. The prostate cancer diagnostic market is expected to show significant growth over the forecast period owing to the increasing prevalence of prostate cancer and technological advancements. The biopsy is expected to be the dominant diagnostic tool in prostate cancer diagnosis as it is mandatory to determine the presence of a cancerous lump and the cause of a high level of prostate-specific antigen (PSA). Imagining prostate cancer diagnosis is expected to rise in the forecasted period due to technological advances in imaging such as a newer approach to measuring blood flow within the gland using a technique called color doppler ultrasound. It detects tumors more accurately. ConfirmMDx is an advanced diagnosis method which is a test that looks at certain genes in the cells from a prostate biopsy sample for accurate diagnosis. Multi-parametric MRI is a newer technique that can be used to help determine the extent of the cancer and how severe it might be.

Prostate Cancer Diagnostic Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.6%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific
Prostate Cancer Diagnostic Market Dynamics

Increase in prostate cancer awareness, lifestyle changes and technological advances are boosting the prostate cancer diagnostic market. Diagnosis and treatment available for prostate cancer are expensive and are associated with several side effects like urinary incontinence, surgical risks like stroke, heart attack, blood clots, which may hinder the prostate cancer diagnostic market over the forecasted period.

Prostate Cancer Diagnostic Market Segmentation

By Test Type
  • Tumor Biomarker Tests
  • Imaging
  • Biopsy
  • Other
By Cancer Stage
  • Stage I
  • Stage II A
  • Stage II B
  • Stage III
  • Stage IV
By End User
  • Hospital Associated Labs
  • Independent Diagnostic Labs
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Abbott Laboratories
  • OPKO
  • Siemens Healthcare
  • DiaSorin
  • BioMeriux
  • Roche
  • MDx Health
  • Beckman Coulter
  • Myriad Genetics
  • Ambry Genetics
  • Genomic Health

Adjacent Markets